



## IBA Signs Contract to Install Proteus®ONE Proton Therapy System in Taiwan

### First Contract in Asia Pacific for IBA's New Compact Single-Room PT Solution

Louvain-la-Neuve, Belgium, July 1<sup>st</sup>, 2013 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has signed a contract with TMS (Tomorrow Medical Systems Co. Ltd.) for the installation of its single-room proton therapy system Proteus®ONE\* in Taiwan. The contract signed in Taipei, includes the delivery of the Proteus®ONE equipment as well a long term maintenance agreement which together will have a value between EUR 30 to 35 million to IBA. The delivery of the equipment is expected to take place in 2015.

This will be the first installation of a Proteus®ONE in Asia and follows on from the first systems soon to be installed in Shreveport, Louisiana, USA, and in Europe, in Nice, France.

The Proteus®ONE system has been developed by IBA to allow more patients globally to access proton therapy. Proteus®ONE is a smaller, less expensive and faster to install proton therapy solution, encompassing the latest in proton therapy technologies, including Pencil Beam Scanning.

TMS is part of the CHC Healthcare Group (CHC), listed on the Taipei stock exchange. TMS operates radiotherapy services for a number of medical centers in Taiwan.

**Olivier Legrain, Chief Executive Officer of IBA commented:** "This contract demonstrates IBA's continued success in Asia and the first contract in the region for our new compact proton therapy system, Proteus®ONE. Making proton therapy smaller and more affordable, without jeopardizing cutting edge technology is a key strategic goal of IBA's and the Proteus®ONE system does exactly that, whilst continuing to provide the most accurate form of radiation therapy available. We look forward to working with our local partners in Taiwan to provide patients across the region with access to the benefits of proton therapy."

**Pei-lin Lee, President of CHC Group:** "CHC is very happy to partner with IBA to install a Proteus®ONE system in Taiwan. Proteus®ONE allows patients to be treated with Intensity Modulated Proton Therapy using Pencil Beam Scanning Technology which will greatly benefit cancer patients in Taiwan."



## Notes to Editors

### About Proton Therapy

Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving patient outcomes and quality of life.

Today, more than half of proton therapy clinical facilities worldwide are IBA systems. This includes 15 proton therapy centers in operation and 11 additional centers under development. Over 20 000 patients have been treated on IBA equipment – more than on all major competitive installations combined.

### About Proteus<sup>®</sup> ONE\*

IBA Proteus<sup>®</sup> ONE is a compact single-room proton therapy solution. It benefits from the latest technologies of Proteus<sup>®</sup> PLUS, developed over the years with top clinical institutions worldwide. Proteus<sup>®</sup> ONE is the safest way to compact Intensity Modulated Proton Therapy (IMPT), the most advanced radiotherapy treatment modality. Proteus<sup>®</sup> ONE is IBA's response to make protons affordable: it is smaller, more affordable, easier to install, easier to operate and ultimately easier to finance. With Proteus<sup>®</sup> ONE, protons are possible for more patients worldwide.

*\*Proteus<sup>®</sup> ONE is the brand name of a new configuration of the Proteus<sup>®</sup> 235, including some new developments subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before marketing.*

### About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.

The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company



is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange Euronext. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

**About CHC**

CHC Healthcare Group (CHC) is a leading Taiwan full healthcare service solution provider for high-end radiation therapy, radiology, neurosurgery, ophthalmology and dentistry equipment. Since 2009, CHC installations of radiotherapy equipment have accounted for 80% of the total Taiwanese market. CHC is the exclusive master distributor for a portfolio of global brand names and has over 60+ certified experienced service engineers providing world class after sales support and maintenance services. Website: [www.cyhc.com.tw](http://www.cyhc.com.tw)

**For further information please contact:**

**IBA**

Jean-Marc Bothy  
Chief Financial Officer  
+32 10 475 890  
[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)

Thomas Ralet  
Vice-President Corporate Communication  
+32 10 475 890  
[thomas.ralet@iba-group.com](mailto:thomas.ralet@iba-group.com)

**For media and investor enquiries:**

**M:Communications**

Amber Bielecka, Mary-Jane Elliott, Matthew Neal  
+44 (0) 207 920 2333  
[IBA@mcomgroup.com](mailto:IBA@mcomgroup.com)